Firm misled investors on Alzheimer's drug, SEC charges
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The U.S. Securities and Exchange Commission fined Cassava Sciences $40 million. This penalty addresses allegations of misleading investors about the quality of their research into simufilam, a potential Alzheimer's disease treatment.
Area Of Science
- Biotechnology
- Neuroscience
- Pharmaceuticals
Background
- Cassava Sciences has been developing simufilam as a potential treatment for Alzheimer's disease.
- Concerns were raised regarding the integrity and validity of the research data supporting simufilam's efficacy.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.